6-[3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl]-1-((R)-1-ethoxymethyl-2-hydroxyethyl)-7-ethyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | 1000161-53-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-[3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl]-1-((R)-1-ethoxymethyl-2-hydroxyethyl)-7-ethyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
• 英文别名: 6-[(3-chloro-2-fluoro-5-morpholin-4-ylphenyl)methyl]-1-[(2R)-1-ethoxy-3-hydroxypropan-2-yl]-7-ethyl-4-oxoquinoline-3-carboxylic acid
• CAS: 1000161-53-4
• 化学式: C₂₈H₃₂ClFN₂O₆
• 分子量: 547.023
• InChiKey: ZUPBCTFQXZUZPA-OAQYLSRUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  38
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  99.5
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  ethyl 6-[(3-chloro-2-fluoro-5-morpholin-4-ylphenyl)methyl]-1-[(2R)-1-ethoxy-3-hydroxypropan-2-yl]-7-ethyl-4-oxoquinoline-3-carboxylate 在 lithium hydroxide 、 水 、 柠檬酸 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以91%的产率得到6-[3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl]-1-((R)-1-ethoxymethyl-2-hydroxyethyl)-7-ethyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
  参考文献：
  名称：

  6- (Heterocyclyl-substituted Benzyl) -4-Oxoquinoline Compound and Use Thereof as HIV Integrase Inhibitor

  摘要：

  本发明涉及以下式[I]所表示的化合物，其中每个符号如规范中所定义，或其药学上可接受的盐，或其溶剂合物，以及含有此类化合物的药物组合物，抗HIV药物和HIV整合酶抑制剂。本发明的化合物具有HIV整合酶抑制活性，并可用作抗HIV药物，或用作艾滋病的预防或治疗药物。此外，通过与其他抗HIV药物（如蛋白酶抑制剂、逆转录酶抑制剂等）的联合使用，可以使其成为更有效的抗HIV药物。由于它显示出整合酶特异性的高抑制活性，该化合物可以成为对人体安全的药物，仅引起较少的副作用。

  公开号：

  US20080207618A1

文献信息

• 6-(HETEROCYCLE-SUBSTITUTED BENZYL)-4-OXOQUINOLINE COMPOUND AND USE OF THE SAME AS HIV INTEGRASE INHIBITOR
  申请人：Japan Tobacco, Inc.

  公开号：EP2033954A1

  公开（公告）日：2009-03-11

  The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutical composition, an anti-HIV agent and an HIV integrase inhibitor containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an anti-HIV agent, or as an agent for the prophylaxis or treatment of AIDS. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agnet. Because it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.

  本发明涉及下式[I]所代表的化合物 其中各符号如说明书中所定义，或其药学上可接受的盐，或其溶液，以及含有这种化合物的药物组合物、抗HIV剂和HIV整合酶抑制剂。本发明的化合物具有抑制 HIV 整合酶的活性，可用作抗 HIV 制剂或预防或治疗艾滋病的制剂。此外，通过与蛋白酶抑制剂、逆转录酶抑制剂等其他抗艾滋病毒药物联合使用，它可以成为一种更有效的抗艾滋病毒agnet。由于该化合物对整合酶具有特异性的高抑制活性，因此是一种对人体安全的药剂，副作用较小。
• 6-(Heterocycle-Substituted Benzyl)-4-Oxoquinoline Compound and Use of the Same as HIV Integrase Inhibitor
  申请人：Japan Tobacco, Inc.

  公开号：EP2368880A1

  公开（公告）日：2011-09-28

  The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutical composition, an anti-HIV agent and an HIV integrase inhibitor containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an anti-HIV agent, or as an agent for the prophylaxis or treatment of AIDS. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agnet. Because it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.

  本发明涉及下式[I]所代表的化合物 其中各符号如说明书中所定义，或其药学上可接受的盐，或其溶液，以及含有这种化合物的药物组合物、抗HIV剂和HIV整合酶抑制剂。本发明的化合物具有抑制 HIV 整合酶的活性，可用作抗 HIV 制剂或预防或治疗艾滋病的制剂。此外，通过与蛋白酶抑制剂、逆转录酶抑制剂等其他抗艾滋病毒药物联合使用，它可以成为一种更有效的抗艾滋病毒agnet。由于该化合物对整合酶具有特异性的高抑制活性，因此是一种对人体安全的药剂，副作用较小。
• US7872004B2
  申请人：——

  公开号：US7872004B2

  公开（公告）日：2011-01-18
• 6- (Heterocyclyl-substituted Benzyl) -4-Oxoquinoline Compound and Use Thereof as HIV Integrase Inhibitor
  申请人：SATOH Motohide

  公开号：US20080207618A1

  公开（公告）日：2008-08-28

  The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutical composition, an anti-HIV agent and an HIV integrase inhibitor containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an anti-HIV agent, or as an agent for the prophylaxis or treatment of AIDS. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agent. Because it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.

  本发明涉及以下式[I]所表示的化合物，其中每个符号如规范中所定义，或其药学上可接受的盐，或其溶剂合物，以及含有此类化合物的药物组合物，抗HIV药物和HIV整合酶抑制剂。本发明的化合物具有HIV整合酶抑制活性，并可用作抗HIV药物，或用作艾滋病的预防或治疗药物。此外，通过与其他抗HIV药物（如蛋白酶抑制剂、逆转录酶抑制剂等）的联合使用，可以使其成为更有效的抗HIV药物。由于它显示出整合酶特异性的高抑制活性，该化合物可以成为对人体安全的药物，仅引起较少的副作用。